|
1
|
Yang DH, Park JS, Jin CJ, et al: The
dysfunction and abnormal signaling pathway of dendritic cells
loaded by tumor antigen can be overcome by neutralizing VEGF in
multiple myeloma. Leuk Res. 33:665–670. 2009. View Article : Google Scholar
|
|
2
|
Dong B, Sun L, Wu X, et al: Vaccination
with TCL plus MHSP65 induces anti-lung cancer immunity in mice.
Cancer Immunol Immunother. 59:899–908. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kuang DM, Zhao Q, Xu J, Yun JP, Wu C and
Zheng L: Tumor-educated tolerogenic dendritic cells induce CD3
down-regulation and apoptosis of T cells through oxygen-dependent
pathways. J Immunol. 181:3089–3098. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kuang DM, Wu Y, Chen N, Cheng J, Zhuang SM
and Zheng L: Tumor-derived hyaluronan induces formation of
immunosuppressive macrophages through transient early activation of
monocytes. Blood. 110:587–595. 2007. View Article : Google Scholar
|
|
5
|
Li H, Zhu H, Xu CJ and Yuan J: Cleavage of
BID by caspase 8 mediates the mitochondrial damage in the Fas
pathway of apoptosis. Cell. 94:491–501. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chuster N and Krieglstein K: Mechanisms of
TGF-beta-mediated apoptosis. Cell Tissue Res. 307:1–14. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Niehans GA, Brunner T, et al: Human lung
carcinomas express Fas ligand. Cancer Res. 57:1007–1012.
1997.PubMed/NCBI
|
|
8
|
Gutierrez LS, Eliza M, Niven-Fairchild T,
Naftolin F and Mor G: The Fas/Fas-ligand system: a mechanism for
immune evasion in human breast carcinomas. Breast Cancer Res Treat.
54:245–253. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Saji H, Nakamura H, Awut H, et al:
Significance of expression of TGF-β in pulmonary metastasis in
non-small cell lung cancer tissues. Ann Thorac Cardiovasc Surg.
9:295–300. 2003.
|
|
10
|
Imai K, Minamiya Y, Goto A, et al:
Bronchioloalveolar invasion in non-small cell lung cancer is
associated with expression of transforming growth factor-β1. World
J Surg Oncol. 11:1132013.PubMed/NCBI
|
|
11
|
Kim HR, Wheeler MA, Wilson CM, et al:
Hyaluronan facilitates invasion of colon carcinoma cells in vitro
via interaction with CD44. Cancer Res. 64:4569–4576. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Anttila MA, Tammi RH, Tammi MI, Syrjanen
KJ, Saarikoski SV and Kosma VM: High levels of stromal hyaluronan
predict poor disease outcome in epithelial ovarian cancer. Cancer
Res. 60:150–155. 2000.PubMed/NCBI
|
|
13
|
Auvinen P, Tammi R, Parkkinen J, et al:
Hyaluronan in peritumoral stroma and malignant cells associates
with breast cancer spreading and predicts survival. Am J Pathol.
156:529–536. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Subramanian G, Schwarz RE and Higgins L:
Targeting endogenous transforming growth factor beta receptor
signaling in SMAD4-deficient pancreatic carcinoma cells inhibits
their invasive phenotypel. Cancer Res. 64:5200–5211. 2004.
View Article : Google Scholar
|
|
15
|
Grimm M, Gasser M, Bueter M, et al:
Evaluation of immunological escape mechanisms in a mouse model of
colorectal liver metastases. BMC Cancer. 10:822010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jansen T, Tyler B, Mankowski JL, et al:
FasL gene knock-down therapy enhances the antiglioma immune
response. Neuro Oncol. 12:482–489. 2010.PubMed/NCBI
|
|
17
|
Hahne M, Rimoldi D, Schroter M, et al:
Melanoma cell expressing of Fas (Apo1-1/CD95) ligand: implications
for tumor immune escape. Science. 274:1363–1366. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Haidong D, Scott ES, Diva RS, et al:
Tumor-associated B7-H1 promotes T-cell apoptosis: a potential
mechanism of immune evasion. Nature Med. 8:793–800. 2002.PubMed/NCBI
|
|
19
|
Quesnel B: Tumor dormancy and
immunoescape. APMIS. 116:685–694. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Attia P, Powell DJ Jr, Maker AV, Kreitman
RJ, Pastan I and Rosenberg SA: Selective elimination of human
regulatory T lymphocytes in vitro with the recombinant immunotoxin
LMB-2. J Immunother. 29:208–214. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Radstake TR, van Bon L, Broen J, et al:
Increased frequency and compromised function of T regulatory cells
in systemic sclerosis (SSc) is related to a diminished CD69 and
TGFb expression. PLoS One. 4:e59812009. View Article : Google Scholar
|
|
22
|
Chiang CL, Benencia F and Coukos G: Whole
tumor antigen vaccines. Semin Immunol. 22:132–143. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kawahara M and Takaku H: Intradermal
immunization with combined baculovirus and tumor cell lysate
induces effective antitumor immunity in mice. Int J Oncol.
43:2023–2030. 2013.PubMed/NCBI
|
|
24
|
Mytar B, Woloszyn M, Szatanek R, et al:
Tumor cell-induced deactivation of human monocytes. J Leukoc Biol.
74:1094–1101. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Mantovani A, Sozzani S, Locati M, Allavena
P and Sica A: Macrophage polarization: tumor-associated macrophages
as a paradigm for polarized M2 mononuclear phagocytes. Trends
Immunol. 23:549–555. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kryczek I, Wei S, Zou L, et al: Cutting
edge: induction of B7–H4 on APCs through IL-10: novel suppressive
mode for regulatory T cells. J Immunol. 177:40–44. 2006.
|
|
27
|
Bennett MW, O’connell J, O’sullivan GC, et
al: Expression of Fas ligand by human gastric adenocarcinomas: a
potential mechanism of immune escape in stomach cancer. Gut.
44:156–162. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Derynck R, Akhurst RJ and Balmain A:
TGF-beta signaling in tumor suppression and cancer progression. Nat
Genet. 29:117–129. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Pajusto M, Ihalainen N, Pelkonen J, et al:
Human in vivo activated CD45R0(+) CD4(+) T
cells are susceptible to spontaneous apoptosis that can be
inhibited by the chemokine CXCL12 and IL-2, -6. -7 and -15. Eur J
Immunol. 34:2771–2780. 2004.PubMed/NCBI
|
|
30
|
Esplugues E, Vega-Ramos J, Cartoixa D, et
al: Induction of tumor NK-cell immunity by anti-CD69 antibody
therapy. Blood. 105:4399–4406. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ralainirina N, Poli A, Michel T, Poos L,
Andrès E, Hentges F and Zimmer J: Control of NK cell functions by
CD4+CD25+ regulatory T cells. J Leukoc Biol. 81:144–153. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Radosavljević GD, Jovanović IP, Kanjevac
TV and Arsenijević NN: The role of regulatory T cells in the
modulation of anti-tumor immune response. Srp Arh Celok Lek.
141:262–267. 2013.(In Serbian).
|
|
33
|
David S, Manuel G and Francisco SM: CD69
is an immunoregulatory molecule induced following activation.
Trends Immunol. 26:136–140. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Freedman RS, Kudelka AP, Kavanagh JJ, et
al: Clinical and biological effects of intraperitoneal injections
of recombinant interferongamma and recombinant interleukin 2 with
or without tumor-infiltrating lymphocytes in patients with ovarian
or peritoneal carcinoma. Clin Cancer Res. 6:2268–2278. 2000.
|
|
35
|
Esplugues E, Sancho D, Vega-Ramos J, et
al: Enhanced antitumor immunity in mice deficient in CD69. J Exp
Med. 197:1093–1106. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Schwenk R, Banania G, Epstein J, et al: Ex
vivo tetramer staining and cell surface phenotyping for early
activation markers CD38 and HLA-DR to enumerate and characterize
malaria antigen-specific CD8+ T-cells induced in human
volunteers immunized with a Plasmodium falciparum
adenovirus-vectored malaria vaccine expressing AMA1. Malar J.
12:3762013. View Article : Google Scholar
|
